Literature DB >> 35610506

Occurrence of pulmonary oil microembolism (POME) with intramuscular testosterone undecanoate injection: literature review.

Jarren A Adam1, Alexander W Pastuszak2, Michael B Christensen3, Rachel Spencer4, Ashlynn Sandberg5, James M Hotaling6, Larry I Lipshultz7.   

Abstract

Testosterone undecanoate injections (TU), an oil-based depot, is a universal hormonal-based treatment which has been associated with pulmonary oil microembolism (POME). However, the rate of POME during routine intramuscular (IM) TU injection is unknown. Here, we conduct a peer-reviewed literature review investigating POME incidents in the setting of TU injections. A total of 48 articles were selected in the literature review, which included 29 studies that used TU and reported its effects. Relatively few POME cases were reported across multiple published studies, including those that focused particularly on the occurrence rate of POME while administrating IM TU. Of the 29 individual studies, which included 7 978 patients, eight studies reported a total of 88 incidence of POME cases or cough. This included episodes of cough that were not originally declared as POME. One post market review reported 223 cases per 3,107,652 injections. When POME did occur, almost all cases resolved spontaneously within 60 min without intervention. Overall, POME was observed to be rare.
© 2022. The Author(s), under exclusive licence to Springer Nature Limited.

Entities:  

Year:  2022        PMID: 35610506     DOI: 10.1038/s41443-022-00585-1

Source DB:  PubMed          Journal:  Int J Impot Res        ISSN: 0955-9930            Impact factor:   2.896


  34 in total

1.  Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men.

Authors:  Christina Wang; Glenn Cunningham; Adrian Dobs; Ali Iranmanesh; Alvin M Matsumoto; Peter J Snyder; Thomas Weber; Nancy Berman; Laura Hull; Ronald S Swerdloff
Journal:  J Clin Endocrinol Metab       Date:  2004-05       Impact factor: 5.958

2.  Efficacy and safety of long-acting intramuscular testosterone undecanoate in aging men: a randomised controlled study.

Authors:  Wei Shen Tan; Wah Yun Low; Chirk Jenn Ng; Wei Keith Tan; Seng Fah Tong; Christopher Ho; Ee Ming Khoo; George Lee; Boon Cheok Lee; Verna Lee; Hui Meng Tan
Journal:  BJU Int       Date:  2013-04-12       Impact factor: 5.588

3.  Initial Clinical Experience With Testosterone Undecanoate Therapy (AVEED) in Men With Testosterone Deficiency in the United States.

Authors:  Yonah Krakowsky; William Conners; Emily Davidson; Alex Rawji; Abraham Morgentaler
Journal:  Urology       Date:  2017-07-19       Impact factor: 2.649

4.  Complications of injectable testosterone undecanoate in routine clinical practice.

Authors:  T Middleton; L Turner; C Fennell; S Savkovic; V Jayadev; A J Conway; D J Handelsman
Journal:  Eur J Endocrinol       Date:  2015-01-30       Impact factor: 6.664

Review 5.  Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline.

Authors:  Shalender Bhasin; Glenn R Cunningham; Frances J Hayes; Alvin M Matsumoto; Peter J Snyder; Ronald S Swerdloff; Victor M Montori
Journal:  J Clin Endocrinol Metab       Date:  2010-06       Impact factor: 5.958

6.  Tolerability of intramuscular injections of testosterone ester in oil vehicle.

Authors:  M A Mackey; A J Conway; D J Handelsman
Journal:  Hum Reprod       Date:  1995-04       Impact factor: 6.918

7.  Multicenter contraceptive efficacy trial of injectable testosterone undecanoate in Chinese men.

Authors:  Yiqun Gu; Xiaowei Liang; Weixiong Wu; Minli Liu; Shuxiu Song; Lifa Cheng; Liwei Bo; Chengliang Xiong; Xinghai Wang; Xiaozhang Liu; Lin Peng; Kangshou Yao
Journal:  J Clin Endocrinol Metab       Date:  2009-03-17       Impact factor: 5.958

8.  Long acting testosterone undecanoate therapy in men with hypogonadism: results of a pharmacokinetic clinical study.

Authors:  Abraham Morgentaler; Adrian S Dobs; Joel M Kaufman; Martin M Miner; Ridwan Shabsigh; Ronald S Swerdloff; Christina Wang
Journal:  J Urol       Date:  2008-10-18       Impact factor: 7.450

9.  A comparison of a novel testosterone bioadhesive buccal system, striant, with a testosterone adhesive patch in hypogonadal males.

Authors:  Márta Korbonits; Marc Slawik; Derek Cullen; Richard J Ross; Günter Stalla; Harald Schneider; Martin Reincke; Pierre M Bouloux; Ashley B Grossman
Journal:  J Clin Endocrinol Metab       Date:  2004-05       Impact factor: 5.958

10.  New testosterone buccal system (Striant) delivers physiological testosterone levels: pharmacokinetics study in hypogonadal men.

Authors:  Christina Wang; Ronald Swerdloff; Mark Kipnes; Alvin M Matsumoto; Adrian S Dobs; Glenn Cunningham; Laurence Katznelson; Thomas J Weber; Theodore C Friedman; Peter Snyder; Howard L Levine
Journal:  J Clin Endocrinol Metab       Date:  2004-08       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.